Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

NICU Antibiotics and Outcomes Trial

ClinicalTrials.gov ID: NCT03997266

Public ClinicalTrials.gov record NCT03997266. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of the NANO trial is to study the longstanding clinical practice of empirically administering intravenous antibiotics to extremely low birthweight (ELBW) infants in the first days of life. In this 802-subject multicenter placebo-controlled randomized clinical trial, the hypothesis to be tested is that the incidence of adverse outcomes is higher in babies receiving empiric antibiotics (EA) in the first week of life compared to babies receiving placebo. The study targets a population of ELBW infants in whom the clinical decision to use or not use EA is currently most challenging -- infants that are clinically stable that did not have a known exposure to intraamniotic infection and were not born preterm for maternal indications. The primary outcome is the composite outcome of late-onset sepsis (LOS), necrotizing enterocolitis (NEC), or death during the index hospitalization. Secondary safety outcomes will include total antibiotic days, days to full enteral feedings, and common morbidities in preterm infants that have previously been linked to EA, e.g. retinopathy of prematurity and bronchopulmonary dysplasia. Weight and length z-score, and head circumference, are standard measures to be collected weekly by clinical team per a standardized protocol.

Study identification

NCT ID
NCT03997266
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Michael Morowitz
Other
Enrollment
359 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Up to 4 Hours
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 4, 2020
Primary completion
Jan 14, 2026
Completion
Jan 14, 2026
Last update posted
Apr 23, 2026

2020 – 2026

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
USA Children's and Women's Hospital Mobile Alabama 36688
Sharp Mary Birch Hospital for Women & Newborns San Diego California 92123
Yale University School of Medicine New Haven Connecticut 06520-8064
University of South Flordia Health Tampa Florida 33606
University of Louisville Research Foundation Inc./Kosair Charities Pediatric Clinical Research Unit Louisville Kentucky 40202
The Trustees of Columbia University in the City of New York New York New York 10032-3702
Golisano Children's Hospital at University of Rochester Rochester New York 14642
Maria Fareri Children's Hospital at Westchester Medical Center Valhalla New York 10595
Atrium Health Wake Forest Baptist Winston-Salem North Carolina 27157
Penn State Medical College Hershey Pennsylvania 17033
Pennsylvania Hospital/The Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Alfred I. duPont for Children of the Nemours Foundation Philadelphia Pennsylvania 19107
Magee Womens Hospital Pittsburgh Pennsylvania 15213
University of Texas Health Science Center at San Antonio San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03997266, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 23, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03997266 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →